8. 很久很久以後…...
有一個分子叫做腫瘤壞死因
子被發現，但是不知道有什
麼用。
In 1975 Dr. Lloyd J.
Old from New York,
reported another cytotoxic
factor produced
by macrophages and
named it tumor necrosis
factor (TNF).[12] from
Wikipedia
從1998，對抗腫瘤壞死因子
的藥物一個一個的出來了：
恩博、復邁、欣普尼。
8
14. TW1605483515-05-16
MEASURE 2: ASAS20 在未使用過生物製劑病人的效果
14
Over 80% of biologic-naïve patients achieved an ASAS20 response at 1year 2,3
*p<0.0001: †p<0.001: §p<O.O1: ‡p<0.05 vs. placebo (p-value for overall population at Week 16 adjusted for
multiplicity). Observed data are presented from Week 20 to 52 (from patients entering the long-term extension).
1. Baeten D, et al. N Engl J Med 2015;373:2534–2548. 2. Baeten D, et al. Arthritis Rheum
2015;67(S10):3482: Poster 2890 at the American College of Rheumatology (ACR), 1 0 November 2015,
San Francisco, USA. 3.Novartis Data on File 2015. MEASURE 2 Clinical Study Report.
15. TW1605483515-05-16
MEASURE 2: ASAS20 在抗腫瘤壞死因子藥物無效病人的效果
15
1 in 2 patients with an inadequate response to anti-TNF therapy ¶ achieved an ASAS20 response at Week 16
vs. 24% with placebo1, 2
§p<0.01; ‡p<0.05 vs. placebo; ¶Patients had received not more than 1 anti-TNF agent prior to enrolment in the study.
Observed data are presented from Week 20 to 52
1. Baeten D, et al. Arthritis Rheum 2015;67(S10):3482: Poster 2890 at the American College of Rheumatology
(ACR), 1 0 November 2015, San Francisco, USA. 2.Novartis Data on File 2015. MEASURE 2 Clinical Study Report.
16. TW1605483515-05-16
Cosentyx® 每月一次的治療時程
建議每次劑量為150 mg，起始於第0，1，2，3和4週皮下注射，接著於第4週開始每4
週注射
Biologic-naive patients with active AS- 150 mg
Inadequate response to, or who cannot tolerate, anti-TNF therapy- 150 mg
16
Cosentyx Summary of Product Characteristics.
